stockrowBiohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
Follow BHVN
Alert me
Biohaven Ltd. (BHVN) Return on equity
Biohaven Ltd.'s return on equity over the twelve months to 30 September 2026 was 940.5%, up 1251.2 percentage points from fiscal 2025 (−310.8%). Over the past ten years it has ranged from −737.0% (fiscal 2019) to 289.8% (fiscal 2016); the current reading is higher than 27% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −310.8% | (111.92) |
| FY2024 | −198.8% | (114.39) |
| FY2023 | −84.4% | 114.45 |
| FY2022 | −198.9% | (318.50) |
| FY2021 | 119.6% | 60.22 |
| FY2020 | 59.4% | 796.42 |
| FY2019 | −737.0% | (566.70) |
| FY2018 | −170.3% | 149.89 |
| FY2017 | −320.2% | (610.02) |
| FY2016 | 289.8% | 244.01 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. | 940.5% |
| AUPH Aurinia Pharmaceuticals Inc compare | 61.4% |
| ADMA ADMA Biologics Inc compare | 42.0% |
| VCEL Vericel Corporation compare | 9.44% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| CLDX Celldex Therapeutics, Inc. compare | −43.9% |
| PVLA Palvella Therapeutics, Inc. compare | −46.6% |
| IMNM Immunome, Inc. compare | −64.0% |
| VERA Vera Therapeutics, Inc. compare | −91.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)